<DOC>
	<DOCNO>NCT01352416</DOCNO>
	<brief_summary>The objective study show ranolazine safe , viable potent alternative post-operative atrial fibrillation suppression patient undergoing cardiac surgery</brief_summary>
	<brief_title>Suppression Of Atrial Fibrillation With Ranolazine After Cardiac Surgery</brief_title>
	<detailed_description>A single center , double blind , prospective , randomized study patient schedule elective cardiac surgery ( Coronary Artery Bypass Graft [ CABG ] , valve CABG valve ) . All patient meet criterion prospectively enrol randomized fashion . Patients enrol assigned receive twice daily identical capsule contain either placebo ranolazine . Study drug initiate 2 day surgery . Patients receive study drug throughout hospitalization keep full 2 week post operatively . Patients see 2 week receive 30 day follow contact visit .</detailed_description>
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Verapamil</mesh_term>
	<mesh_term>Diltiazem</mesh_term>
	<mesh_term>Ranolazine</mesh_term>
	<criteria>Indications cardiac surgery ( CABG , valve surgery CABG valve surgery , Able provide inform consent . Documented atrial fibrillation within previous 3 month Ongoing therapy suppressive antiarrhythmic drug Patient currently digoxin Emergent surgery Patient receive hemodialysis Concomitant use ketoconazole , diltiazem , verapamil Known tolerance hypersensitivity ranolazine Pregnant individual MAZE procedure ( surgical ablation treat atrial fibrillation ) perform concurrent cardiac surgery</criteria>
	<gender>All</gender>
	<minimum_age>22 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Suppress Atrial Fibrillation</keyword>
	<keyword>heart bypass surgery</keyword>
	<keyword>heart valve surgery</keyword>
</DOC>